BlueRock Therapeutics (Acquisition)

Funding Details
Awarder
Inbox
Date Award
August 08, 2019
Vertical
Biotechnology
Funding URL
View Funding Page
Valuation
$1,000,000

Company Info
Founding Year
2016
Traction
BlueRock Therapeutics will continue to operate as an independent company with a focus on developing cell therapies in neurology, cardiology, and immunology.
Organizations Involved
Bayer AG, Versant Ventures
Company Description
BlueRock Therapeutics is a biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology, and immunology using a proprietary induced pluripotent stem cell (iPSC) platform. Bayer will fully acquire BlueRock Therapeutics, with an initial focus in neurology, cardiology, and immunology.
Market
Neurology, Cardiology, Immunology
Location
Cambridge, MA, US
Coinvestors
Versant Ventures

Links
Back to Home Back to Biotechnology Deals View Funding Announcement